Mehmet Mihmanli

Mehmet Mihmanli

Auto-generated profile, based on publicly available information

Mehmet Mihmanli

General Surgery Clinic, Sisli Hamidiye Etfal Education and Research Hospital, Halaskargazi Cad. Etfal Sok., 34371 Sisli, Istanbul Turkey

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in World Journal of Hepatology
Verified
Journal Article
Open access
MMMemmet Mihmanli
Memmet Mihmanli
UIUfuk Oguz Idiz
Ufuk Oguz Idiz
CKCemal Kaya
Cemal Kaya
UDUygar Demir
Uygar Demir
OBOzgur Bostanci
Ozgur Bostanci
EBEmre Bozkurt
Emre Bozkurt
Echinococcus granulosus (E. granulosus) and Echinococcus multilocularis (E. multilocularis) infections are the most common parasitic diseases that affect the liver. The disease course is typically slow and the patients tend to remain asymptomatic for many years. Often the diagnosis is incidental. Right upper quadrant abdominal pain, hepatitis, cholangitis, and anaphylaxis due to dissemination of the cyst are the main presenting symptoms. Ultrasonography is important in diagnosis. The World Health Organization classification, based on ultrasonographic findings, is used for staging of the disease and treatment selection. In addition to the imaging methods, immunological investigations are used to support the diagnosis. The available treatment options for E. granulosus infection include open surgery, percutaneous interventions, and pharmacotherapy. Aggressive surgery is the first-choice treatment for E. multilocularis infection, while pharmacotherapy is used as an adjunct to surgery. Due to a paucity of clinical studies, empirical evidence on the treatment of E. granulosus and E. multilocularis infections is largely lacking; there are no prominent and widely accepted clinical algorithms yet. In this article, we review the diagnosis and treatment of E. granulosus and E. multilocularis infections in the light of recent evidence.

1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MMMehmet Mihmanli
Mehmet Mihmanli
EIEnver Ilhan
Enver Ilhan
UIUfuk Oguz Idiz
Ufuk Oguz Idiz
AAAli Alemdar
Ali Alemdar
UDUygar Demir
Uygar Demir
Gastric cancer has an important place in the worldwide incidence of cancer and cancer-related deaths. It can metastasize to the lymph nodes in the early stages, and lymph node metastasis is an important prognostic factor. Surgery is a very important part of gastric cancer treatment. A D2 lymphadenectomy is the standard surgical treatment for cT1N+ and T2-T4 cancers, which are potentially curable. Recently, the TNM classification system was reorganized, and the margins for gastrectomy and lymphadenectomy were revised. Endoscopic, laparoscopic and robotic treatments of gastric cancer have progressed rapidly with development of surgical instruments and techniques, especially in Eastern countries. Different endoscopic resection techniques have been identified, and these can be divided into two main categories: endoscopic mucosal resection and endoscopic submucosal dissection. Minimally invasive surgery has been reported to be safe and effective for early gastric cancer, and it can be successfully applied to advanced gastric cancer with increasing experience. Cytoreductive surgery and hyperthermıc intraperıtoneal chemotherapy were developed as a combined treatment modality from the results of experimental and clinical studies. Also, hyperthermia increases the antitumor activity and penetration of chemotherapeutics. Trastuzumab which is a monoclonal antibody interacts with human epidermal growth factor (HER) 2 and is related to gastric carcinoma. The anti-tumor mechanism of trastuzumab is not clearly known, but mechanisms such as interruption of the HER2-mediated cell signaling pathways and cell cycle progression have been reported previously. H. pylori is involved in 90% of all gastric malignancies and Japanese guidelines strongly recommend that all H. pylori infections should be eradicated regardless of the associated disease. In this review, we present innovations discussed in recent studies.

15 September 2004
Verified
Journal Article
Closed access
MMMehmet Mihmanli
Mehmet Mihmanli
EDEce Dilege
Ece Dilege
UDUygar Demir
Uygar Demir
HCHalil Coskun
Halil Coskun
TETulay Eroglu
Tulay Eroglu
MUMehtap D Uysalol
Mehtap D Uysalol

22 April 2016 in SpringerPlus
Verified
Journal Article
Open access
PDF file
MMMehmet Mihmanli
Mehmet Mihmanli
RIRiza Gurhan Isil
Riza Gurhan Isil
EBEmre Bozkurt
Emre Bozkurt
UDUygar Demir
Uygar Demir
CKCemal Kaya
Cemal Kaya
YAYuksel Altuntas
Yuksel Altuntas
Laparoscopic Sleeve Gastrectomy has become one of the most popular bariatric surgery types and helps treating not only obesity but also endocrinological diseases related to obesity. Therefore we aimed to evaluate the effects of laparoscopic sleeve gastrectomy on the treatment of type 2 diabetes. All patients, who underwent morbid obesity surgery during 2013–2014 and had a HbA1c >6 % were included in this prospective study. Demographical data, usage of oral antidiabetic drugs or insulin were recorded, and laboratory findings as HbA1c and fasting plasma glucose were evaluated preoperatively and postoperatively at the 6th and 12th months. Diabetes remission criteria were used to assess success of the surgical treatment. Totally 88 patients were included in this study. 55 patients were using oral antidiabetic drugs and 33 patients were using insulin. At the 6th month complete remission was observed in 80 (90.9 %), partial remission in 3 (3.4 %) and persistent diabetes in 5 (5.6 %) patients. At the 12th month complete remission was observed in 84 (95.4 %), partial remission in 1 (1.1 %) and persistent diabetes in 3 (3.4 %) patients. This study indicated that laparoscopic sleeve gastrectomy surgery achieved a complete remission of diabetes in 95.4 % patients having type 2 diabetes during a 1 year fallow up period. However, complete remission of type 2 diabetes has been reported as 80 % during long term fallow up in the literature. In our opinion this rate may change with longer follow up periods and studies involving more patients suffering type 2 diabetes.

1 July 2004
Verified
Journal Article
Closed access
MMMehmet Mihmanli
Mehmet Mihmanli
MUMehtap Uysalol
Mehtap Uysalol
HCHalil Coskun
Halil Coskun
UDUygar Demir
Uygar Demir
EDEce Dilege
Ece Dilege
TETülay Eroğlu
Tülay Eroğlu

22 April 2020
Verified
Book Chapter
Open access
PDF file
MMMehmet Mihmanli
Mehmet Mihmanli
MTMert Tanal
Mert Tanal
EBEmre Bozkurt
Emre Bozkurt
OGOnur Guven
Onur Guven
Liver hydatid cyst is a disease of zoonosis caused by Echinococcus granulosus or less frequently by Echinococcus multilocularis and Echinococcus oligarthrus. The primary carriers are canines, while human beings are secondary hosts. Early diagnosis is important for cysts not to become complicated and for the treatment not to get difficult. The most effective treatment of uncomplicated hydatid cyst is to reduce the dead space of the cavity and to discharge the fluid as much as possible. However, if the cysts get complex, there is no standard treatment management defined other than offered management options by authors. In complex conditions, the treatment is determined according to the stage of the cyst and the relation of the cyst with biliary ducts or surrounding organs. In this chapter, the treatment regimens of liver hydatid disease mainly based on interventions and surgical operations are going to take a part.